Scilex Holding Company Expands Manufacturing And Secures New Patents
$SCLX
Scilex Holding Company (NASDAQ:SCLX), a leader in non-opioid pain management solutions, recently announced significant advancements in its operational capabilities and intellectual property portfolio. The company has successfully completed a Good Manufacturing Practices (GMP) inspection by the US Food and Drug Administration (FDA) at its enhanced manufacturing facility in Tosu, Saga, Japan. This approval from the FDA marks a pivotal step for Scilex, allowing it to scale up the production of its ZTlido® product to meet increasing demand. The facility, operated by Oishi Koseido Co., Ltd. ., is now approved to produce ZTlido® at a 250kg scale. This expansion is critical as it supports the company’s growth strategy by ensuring a steady supply of its lidocaine topical system, used for the treatment of acute and chronic pain.
Additionally, the facility will also produce SP-103, a triple strength formulation of ZTlido®, which has shown promising results in recent trials for back and neck pain. In a strategic move to fortify its market position, Scilex also announced the acquisition of two new US patents for ZTlido®. These patents, issued by the United States Patent and Trademark Office (USPTO), cover innovative methods and compositions that enhance the effectiveness of lidocaine patches in pain relief. The patents are expected to provide proprietary protection through January 2031, significantly extending the commercial runway for ZTlido®. Furthermore, Scilex has been actively expanding its product distribution.
The company has entered into agreements with major US pharmacy chains to stock ELYXYB®, its FDA-approved solution for acute migraine treatment. This expansion not only broadens the accessibility of Scilex’s products but also strengthens its presence in the pain management sector. These developments underscore Scilex’s commitment to innovation and its strategic focus on non-opioid pain management. By enhancing manufacturing capabilities and securing extended patent protections, Scilex is well-positioned to meet the growing needs of the healthcare market and continue providing effective pain management solutions without the use of opioids. The company moves forward, these advancements are expected to play a key role in its ongoing growth and success in the pharmaceutical industry.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**